Unlike some countries that have “flattened the curve,” the U.S. is experiencing a sharp rise in COVID-19 cases. In this episode, part of a series on the scientific and investment implications of COVID-19, Biotech Analyst Agustin Mohedas explains why the U.S. trajectory has diverged, but also notes that the outbreak’s dynamics are changing, with important implications for the next phase of the pandemic.